Biotech Values

[DewDiligence]

SPHS -42% on patient death:

https://finance.yahoo.com/news/sophiris-bio-reports-top-line-123700590.html

A single administration of topsalysin continues to demonstrate an ability to ablate targeted prostate cancer cells with 10 of 35 patients (29%) demonstrating a clinical response of which 6 patients had a complete ablation with no detectable cancer on targeted biopsy of the treated area.

Separately, Sophiris was recently notified that a patient death occurred on the same day as their second administration. The company is currently investigating the cause and as a precaution no additional patients will receive a second administration of topsalysin.

The word, separately can be a killer.